Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer
Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
ASCO GU 2021: Cabozantinib for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer
The microbes in the gut (the gut microbiome) are a [...]
Cabozantinib plus nivolumab granted FDA approval for first-line treatment of advanced kidney cancer
The Food and Drug Administration (FDA) in the United States has [...]
Obesity diminishes response to immunotherapy in kidney cancer
In this study, the researchers looked at the interaction between [...]
